<DOC>
	<DOCNO>NCT02244580</DOCNO>
	<brief_summary>This prospective examination tumor material breast cancer patient randomize FinHer-trial ( = ( = Comparison vinorelbine docetaxel trastuzumab adjuvant treatment breast cancer patient wirh high risk cancer recurrence ) . The formalin-fixed , paraffin-embedded tissue sample analyse Estrogen receptor 1 ( ESR1 ) , progesterone receptor ( PgR ) , Human epidermal growth factor receptor 2 ( HER2 ) Antigen Ki-67 ( Ki-67 ) molecular vitro diagnostic kit MammaTyper™ . According new subtyping 5 year Distant disease free survival ( DDFS ) Overall survival ( OS ) re-evaluated .</brief_summary>
	<brief_title>Re-Evaluation Tumor Samples From Women With Breast Cancer With Vitro Diagnostic Kit `` MammaTyperTM ''</brief_title>
	<detailed_description>Despite fact reliable measure marker ESR1 , PgR , HER2 , Ki-67 necessary currently use method 20 % determination inaccurate especially Ki67- measure reproducible . Therefore new evaluation system new method necessary improve diagnostic . At least 4 subtypes distinguish date depend expression ESR , PgR , Her2 Ki-67 : - Luminal A-type - Luminal B-type - Her2-type - Triple-negative-type MammaTyper™ use new approach . Instead detection marker protein , messenger ribonucleic adic ( mRNA ) marker protein quantitated . This prospectively plan diagnostic study investigate potential subgrouping patient baseline accord result MammaTyper™ methodology predict survival . Patients subgrouped accord new marker determination DDFS OS evaluate compare DDFS OS subgrouping former marker determination .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>Invasive breast cancer verify histological biopsy Age 65 young Estrogen receptor ( ER ) , PgR HER2 expression determine No distant metastasis present ( M0 ) The patient provide write informed consent study participation The estimate risk breast cancer recurrence high ( 25 % high within first 5 year date diagnosis , &gt; 35 % within first 10 year diagnosis ) Patients breast cancer `` special histological type '' ( mucinous , papillary , medullary , tubular type breast cancer ) metastases present ipsilateral axillary lymph node The WHO performance status moderate/poor , Z &gt; 1 The peripheral blood leukocyte count le 3.0 x 109/L , blood granulocyte count le 1.5 x 109/L , blood thrombocyte count le 120 x 109/L Any physical mental disorder consider prohibit administration chemotherapy Cardiac failure ; severe cardiac arrythmia require regular medication</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Subtyping Invasive breast cancer</keyword>
</DOC>